🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

BRIEF-Intellipharmaceutics receives complete response letter from FDA for Rexista NDA

Published 2017-09-25, 07:14 a/m
BRIEF-Intellipharmaceutics receives complete response letter from FDA for Rexista NDA
IPCIh
-

Sept 25 (Reuters) - Intellipharmaceutics International Inc IPCI.TO :

* Intellipharmaceutics receives complete response letter from the FDA for rexista NDA

* Intellipharmaceutics receives complete response letter from the fda for rexista NDA

* Intellipharmaceutics International Inc - Intellipharmaceutics has been given one year to respond to CRL, and can request additional time if necessary

* Intellipharmaceutics international inc - fda has also requested that Intellipharmaceutics submit an alternate proposed proprietary name for oxycodone ER

* Intellipharmaceutics -do not expect additional category 2, 3 studies FDA requested will impact anticipated commercialization timeline for oxycodone ER

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.